{"title":"新产品引进[cenobamate, dapagliflozin(新适应症),daratumumab和透明质酸酶-fihj(新配方),nintedanib(新适应症),重组人乳头瘤病毒二价(16、18型)疫苗,sacituzumab govitecan(同类首创),tislelizumab, tucatinib]","authors":"","doi":"10.1358/dot.2020.56.6.3169947","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"31 17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New product intros [cenobamate, dapagliflozin (new indication), daratumumab and hyaluronidase-fihj (new formulation), nintedanib (new indication), recombinant human papillomavirus bivalent (types 16, 18) vaccine, sacituzumab govitecan (first-in-class), tislelizumab, tucatinib]\",\"authors\":\"\",\"doi\":\"10.1358/dot.2020.56.6.3169947\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":85144,\"journal\":{\"name\":\"Medicamentos de actualidad. Drugs of today\",\"volume\":\"31 17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicamentos de actualidad. Drugs of today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2020.56.6.3169947\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2020.56.6.3169947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New product intros [cenobamate, dapagliflozin (new indication), daratumumab and hyaluronidase-fihj (new formulation), nintedanib (new indication), recombinant human papillomavirus bivalent (types 16, 18) vaccine, sacituzumab govitecan (first-in-class), tislelizumab, tucatinib]